$BPTH
BIO-PATH HOLDINGS, INC.

2021 Q4 Form 10-Q Financial Statement

#000155837021015489 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.209M $1.088M $970.0K
YoY Change 19.7% 12.16% 7.78%
% of Gross Profit
Research & Development $2.908M $981.0K $2.000M
YoY Change 88.83% -50.95% 44.93%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K $10.00K
YoY Change 0.0% 100.0% -50.0%
% of Gross Profit
Operating Expenses $4.117M $2.069M $2.970M
YoY Change 61.45% -30.34% 30.84%
Operating Profit -$2.069M -$2.970M
YoY Change -30.34%
Interest Expense $1.000K $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $2.000K
YoY Change
Pretax Income -$4.116M -$2.069M -$2.970M
YoY Change 61.41% -30.34% 32.59%
Income Tax
% Of Pretax Income
Net Earnings -$4.116M -$2.069M -$2.968M
YoY Change 61.41% -30.29% 32.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29
Diluted Earnings Per Share -$574.4K -$294.0K -$804.9K
COMMON SHARES
Basic Shares Outstanding 7.160M 6.960M
Diluted Shares Outstanding 7.038M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.77M $26.60M $12.06M
YoY Change 72.78% 120.57% -21.59%
Cash & Equivalents $23.77M $26.60M $12.06M
Short-Term Investments
Other Short-Term Assets $1.843M $1.519M $2.260M
YoY Change 98.6% -32.79% 49.67%
Inventory
Prepaid Expenses $523.0K $2.113M
Receivables
Other Receivables
Total Short-Term Assets $26.14M $30.23M $14.32M
YoY Change 63.83% 111.12% -15.22%
LONG-TERM ASSETS
Property, Plant & Equipment $225.0K $222.0K $560.0K
YoY Change -2.6% -60.36% -21.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $428.0K $447.0K $550.0K
YoY Change -17.53% -18.73% -22.54%
TOTAL ASSETS
Total Short-Term Assets $26.14M $30.23M $14.32M
Total Long-Term Assets $428.0K $447.0K $550.0K
Total Assets $26.57M $30.68M $14.87M
YoY Change 61.26% 106.32% -15.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $100.0K $400.0K $610.0K
YoY Change 0.0% -34.43% 17.31%
Accrued Expenses $800.0K $700.0K $810.0K
YoY Change -20.0% -13.58% 15.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $958.0K $1.162M $1.430M
YoY Change -18.05% -18.74% 17.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $153.0K $172.0K $260.0K
YoY Change -36.25% -33.85% -25.71%
Total Long-Term Liabilities $153.0K $172.0K $260.0K
YoY Change -36.25% -33.85% -25.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $958.0K $1.162M $1.430M
Total Long-Term Liabilities $153.0K $172.0K $260.0K
Total Liabilities $1.111M $1.334M $1.690M
YoY Change -20.93% -21.07% 7.64%
SHAREHOLDERS EQUITY
Retained Earnings -$77.66M -$73.55M
YoY Change 15.53%
Common Stock $7.000K $7.000K
YoY Change 40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.46M $29.35M $13.19M
YoY Change
Total Liabilities & Shareholders Equity $26.57M $30.68M $14.87M
YoY Change 61.26% 106.32% -15.51%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$4.116M -$2.069M -$2.968M
YoY Change 61.41% -30.29% 32.5%
Depreciation, Depletion And Amortization $20.00K $20.00K $10.00K
YoY Change 0.0% 100.0% -50.0%
Cash From Operating Activities -$2.801M -$2.891M -$2.350M
YoY Change 8.15% 23.02% 23.68%
INVESTING ACTIVITIES
Capital Expenditures -$23.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$23.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.000K 1.399M 0.000
YoY Change -100.07% -100.0%
NET CHANGE
Cash From Operating Activities -2.801M -2.891M -2.350M
Cash From Investing Activities -23.00K 0.000
Cash From Financing Activities -3.000K 1.399M 0.000
Net Change In Cash -2.827M -1.492M -2.350M
YoY Change -266.29% -36.51% 35.06%
FREE CASH FLOW
Cash From Operating Activities -$2.801M -$2.891M -$2.350M
Capital Expenditures -$23.00K $0.00
Free Cash Flow -$2.778M -$2.891M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4542000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7160000
dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001133818
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36333
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
742-1357
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BPTH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7160164
CY2021Q3 us-gaap Cash
Cash
26601000
CY2020Q4 us-gaap Cash
Cash
13755000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2113000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1273000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1519000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
928000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
30233000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
15956000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1076000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1029000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
854000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
798000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
222000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
231000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
225000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
288000
CY2021Q3 us-gaap Assets
Assets
30680000
CY2020Q4 us-gaap Assets
Assets
16475000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
417000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
100000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
657000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
975000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
88000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
94000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1162000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1169000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
172000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
236000
CY2021Q3 us-gaap Liabilities
Liabilities
1334000
CY2020Q4 us-gaap Liabilities
Liabilities
1405000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7160000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4542000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102884000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
82286000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73545000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67221000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
29346000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15070000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30680000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16475000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
981000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3002000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5038000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1088000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
970000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3324000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3319000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
2069000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2970000
us-gaap Operating Expenses
OperatingExpenses
6326000
us-gaap Operating Expenses
OperatingExpenses
8357000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2069000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2970000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6326000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8357000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
25000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2069000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2968000
us-gaap Net Income Loss
NetIncomeLoss
-6324000
us-gaap Net Income Loss
NetIncomeLoss
-8332000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.26
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7038
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3692
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6578
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3692
us-gaap Net Income Loss
NetIncomeLoss
-6324000
us-gaap Net Income Loss
NetIncomeLoss
-8332000
us-gaap Share Based Compensation
ShareBasedCompensation
591000
us-gaap Share Based Compensation
ShareBasedCompensation
432000
bpth Operating Lease Right Of Use Assets Amortization
OperatingLeaseRightOfUseAssetsAmortization
63000
bpth Operating Lease Right Of Use Assets Amortization
OperatingLeaseRightOfUseAssetsAmortization
58000
us-gaap Depreciation
Depreciation
56000
us-gaap Depreciation
Depreciation
54000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
840000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
204000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
591000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
489000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
176000
bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
70000
bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
63000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7116000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8368000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15852000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4157000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20009000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12846000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8368000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13755000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20426000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26601000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12058000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
16011000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
143000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2968000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
13186000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
29754000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1399000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
262000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2069000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
29346000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
21086000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
432000
us-gaap Net Income Loss
NetIncomeLoss
-8332000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
13186000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15070000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15852000
bpth Stock Issue During Period Value Warrants Exercised
StockIssueDuringPeriodValueWarrantsExercised
4157000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
591000
us-gaap Net Income Loss
NetIncomeLoss
-6324000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
29346000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1300000
CY2021Q3 bpth Expected Advanced Payment To Be Expensed
ExpectedAdvancedPaymentToBeExpensed
2100000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
400000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
100000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
700000
CY2021Q3 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
300000
CY2021Q3 bpth Accrued Manufacturing And Testing Expenses
AccruedManufacturingAndTestingExpenses
100000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
100000
CY2021Q3 bpth Accrued Clinical And Preclinical Expenses
AccruedClinicalAndPreclinicalExpenses
100000
CY2021Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1000000.0
CY2020Q4 bpth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
400000
CY2020Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000
CY2020Q4 bpth Accrued Manufacturing Expense
AccruedManufacturingExpense
100000
CY2020Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12200000
bpth Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
428907
bpth Weighted Average Exercise Price
WeightedAverageExercisePrice
9.71
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4200000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
486000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.58
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
156000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.83
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
33000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1600000
bpth Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndUnvestedWeightedAverageRemainingContractualTerm
P2Y8M12D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0050
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
274000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
212000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.02
CY2021Q3 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
2200000

Files In Submission

Name View Source Status
0001558370-21-015489-index-headers.html Edgar Link pending
0001558370-21-015489-index.html Edgar Link pending
0001558370-21-015489.txt Edgar Link pending
0001558370-21-015489-xbrl.zip Edgar Link pending
bpth-20210930.xsd Edgar Link pending
bpth-20210930x10q.htm Edgar Link pending
bpth-20210930x10q_htm.xml Edgar Link completed
bpth-20210930xex31d1.htm Edgar Link pending
bpth-20210930xex32.htm Edgar Link pending
bpth-20210930_cal.xml Edgar Link unprocessable
bpth-20210930_def.xml Edgar Link unprocessable
bpth-20210930_lab.xml Edgar Link unprocessable
bpth-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending